8.71% volatility in Recursion Pharmaceuticals Inc (RXRX) last month: This is a red flag warning

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) on Monday, soared 0.60% from the previous trading day, before settling in for the closing price of $5.03. Within the past 52 weeks, RXRX’s price has moved between $3.79 and $12.36.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has dropped its sales by -35.28% annually for the last half of the decade. The company achieved an average annual earnings per share of 15.16%. With a float of $310.65 million, this company’s outstanding shares have now reached $399.15 million.

In terms of profitability, gross margin is -0.08%, operating margin of -960.64%, and the pretax margin is -962.73%.

Recursion Pharmaceuticals Inc (RXRX) Insider Updates

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Recursion Pharmaceuticals Inc is 23.58%, while institutional ownership is 60.54%. The most recent insider transaction that took place on Mar 27 ’25, was worth 836,987. In this transaction Chief Executive Officer of this company sold 138,574 shares at a rate of $6.04, taking the stock ownership to the 1,117,450 shares. Before that another transaction happened on Mar 27 ’25, when Company’s Officer proposed sale 138,574 for $6.04, making the entire transaction worth $836,987.

Recursion Pharmaceuticals Inc (RXRX) Performance Highlights and Predictions

According to the Wall Street analysts, stocks earnings will be around 15.16% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.10% during the next five years compared to -35.28% drop over the previous five years of trading.

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators

Recursion Pharmaceuticals Inc (RXRX) is currently performing well based on its current performance indicators. A quick ratio of 4.11 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 34.40.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.78, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.15 in one year’s time.

Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)

Let’s dig in a bit further. During the last 5-days, its volume was 27.57 million. That was better than the volume of 24.26 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 60.43%.

During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 14.82%, which indicates a significant decrease from 25.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.49% in the past 14 days, which was lower than the 107.01% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $4.91, while its 200-day Moving Average is $6.33. However, in the short run, Recursion Pharmaceuticals Inc’s stock first resistance to watch stands at $5.22. Second resistance stands at $5.37. The third major resistance level sits at $5.48. If the price goes on to break the first support level at $4.96, it is likely to go to the next support level at $4.85. Assuming the price breaks the second support level, the third support level stands at $4.70.

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats

Market capitalization of the company is 2.06 billion based on 406,495K outstanding shares. Right now, sales total 58,840 K and income totals -463,660 K. The company made 14,750 K in profit during its latest quarter, and -202,490 K in sales during its previous quarter.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.